Local surgery or ablation may be most appropriate for patients with a solitary site of locoregional recurrence following definitive surgery for clinically localized renal cell carcinoma, according to investigators.
Researchers determined the most common sites of metastasis and their association with overall survival rate for the 3 main subtypes of RCC.
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
Belzutifan is a potent and selective inhibitor of HIF-2α.
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Higher proportions of patients in the low to middle income brackets were diagnosed with localized renal cell carcinoma in states allowing Medicaid expansion.
Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC.
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
CheckMate 9ER investigators assessed the efficacy of combination nivolumab and cabozantinib in the front-line sarcomatoid renal cell carcinoma (RCC) setting in an extended analysis.
